Комбинированное и комплексное лечение больных раком молочной железы в условиях пандемии новой коронавирусной инфекции (COVID-19)

Комбинированное и комплексное лечение больных раком молочной железы в условиях пандемии новой коронавирусной инфекции (COVID-19)

Автор: Каприн А.Д., Зикиряходжаев А.Д., Босиева А.Р., Самсонов Ю.В., Костин А.А.

Журнал: Сибирский онкологический журнал @siboncoj

Рубрика: Обзоры

Статья в выпуске: 1 т.21, 2022 года.

Бесплатный доступ

Цель исследования - изучить результаты наиболее значимых исследований, представляющие основные принципы диагностики и лечения больных раком молочной железы (РМЖ) в период пандемии coVid-19. материал и методы . Поиск соответствующих источников был осуществлен в системах pubmed, cochrane library, Web of science, изучены публикации за 2019-20 гг., 48 из которых были использованы для написания данного обзора. результаты . В период пандемии coVid-19 необходимо на определённый промежуток времени приостановить проведение скрининговых обследований, больных ранним и метастатическим РМЖ следует перевести на амбулаторное лечение в лечебных учреждениях (ЛУ), находящихся по месту их проживания. Обследования и консультативные приемы пациентов, находящихся в процессе гормонотерапии, должны быть отложены или проводиться с использованием телемедицинских технологий. Лечение больных РМЖ в период пандемии должно проводиться согласно клиническим рекомендациям и протоколам, но минимизируя количество посещений в ЛУ. Заключение. Пандемия новой коронавирусной инфекции (coVid-19) представляет серьезную проблему для здравоохранения и специалистов во всем мире. Все решения по выработке тактики лечения должны приниматься с учетом рисков и преимуществ в контексте каждого этапа пандемии, в индивидуальном порядке и с учетом предпочтений больных.

Еще

Рак молочной железы, новая коронавирусная инфекция, covid-19

Короткий адрес: https://sciup.org/140290562

IDR: 140290562   |   DOI: 10.21294/1814-4861-2022-21-1-99-106

Список литературы Комбинированное и комплексное лечение больных раком молочной железы в условиях пандемии новой коронавирусной инфекции (COVID-19)

  • Wu C., Chen X., Cai Y., Xia J., Zhou X., Xu S., Huang H., Zhang L., Zhou X., Du C., Zhang Y., Song J., Wang S., Chao Y., Yang Z., Xu J., Zhou X., Chen D., Xiong W., Xu L., Zhou F., Jiang J., Bai C., Zheng J., Song Y. Risk Factors Associated With Acute Respiratory Distress Syndrome and Death in Patients With Coronavirus Disease 2019 Pneumonia in Wuhan, China. JAMA Intern Med. 2020; 180(7): 934-43. https://doi.org/10.1001/jamainternmed.2020.0994.
  • Chen N., Zhou M., Dong X., Qu J., Gong F., Han Y., Qiu Y., Wang J., Liu Y., Wei Y., Xia J., Yu T., Zhang X., Zhang L. Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study. Lancet. 2020; 395(10223): 507-13. https://doi.org/10.1016/S0140-6736(20)30211-7.
  • Huang C., Wang Y., Li X., Ren L., Zhao J., Hu Y., Zhang L., Fan G., Xu J., Gu X., Cheng Z., Yu T., Xia J., Wei Y., Wu W., Xie X., Yin W., Li H., Liu M., Xiao Y., Gao H., Guo L., Xie J., Wang G., Jiang R., Gao Z., Jin Q., Wang J., Cao B. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet. 2020; 395(10223): 497-506. https://doi.org/10.1016/S0140-6736(20)30183-5.
  • Channappanavar R., Perlman S. Pathogenic human coronavirus infections: causes and consequences of cytokine storm and immunopathology. Semin Immunopathol. 2017; 39(5): 529-39. https://doi.org/10.1007/s00281-017-0629-x.
  • Yue H., Bai X., Wang J., Yu Q., Liu W., Pu J., Wang X., Hu J., Xu D., Li X., Kang N., Li L., Lu W., Feng T., Ding L., Li X., Qi X; Gansu Provincial Medical Treatment Expert Group of COVID-19. Clinical characteristics of coronavirus disease 2019 in Gansu province, China. Ann Palliat Med. 2020; 9(4): 1404-12. https://doi.org/10.21037/apm-20-887.
  • Richardson S., Hirsch J.S., Narasimhan M., Crawford J.M., McGinn T., Davidson K.W.; the Northwell COVID-19 Research Consortium; Barnaby D.P., Becker L.B., Chelico J.D., Cohen S.L., Cookingham J., Coppa K., Diefenbach M.A., Dominello A.J., Duer-Hefele J., Falzon L., Gitlin J., Hajizadeh N., Harvin T.G., Hirschwerk D.A., Kim E.J., Kozel Z.M., Marrast L.M., Mogavero J.N., Osorio G.A., Qiu M., Zanos T.P. Presenting Characteristics, Comorbidities, and Outcomes Among 5700 Patients Hospitalized With COVID-19 in the New York City Area. JAMA. 2020; 323(20): 2052-9. https://doi.org/10.1001/jama.2020.6775.
  • Hadjadj J., Yatim N., Barnabei L., Corneau A., Boussier J., Smith N., Péré H., Charbit B., Bondet V., Chenevier-Gobeaux C., Breillat P., Carlier N., Gauzit R., Morbieu C., Pène F., Marin N., Roche N., Szwebel T.-A., Merkling S.H., Treluyer J.-M., Veyer D., Mouthon L., Blanc C., Tharaux P.-L., Rozenberg F., Fischer A., Duffy D., Rieux-Laucat F., Kernéis S., Terrier B. Impaired type I interferon activity and inflammatory responses in severe COVID-19 patients. Science. 2020; 369(6504): 718-24. https://doi.org/10.1126/science.abc6027.
  • Mehta P., McAuley D.F., Brown M., Sanchez E., Tattersall R.S., Manson J.J.; HLH Across Speciality Collaboration, UK. COVID-19: consider cytokine storm syndromes and immunosuppression. Lancet. 2020; 395(10229):1033-4. https://doi.org/10.1016/S0140-6736(20)30628-0.
  • Xu Z., Shi L., Wang Y., Zhang J., Huang L., Zhang C., Liu S., Zhao P., Liu H., Zhu L., Tai Y., Bai C., Gao T., Song J., Xia P., Dong J., Zhao J., Wang F.-S. Pathological findings of COVID-19 associated with acute respiratory distress syndrome. Lancet Respir Med. 2020; 8(4): 420-2. https://doi.org/10.1016/S2213-2600(20)30076-X.
  • Livingston E., Bucher K. Coronavirus Disease 2019 (COVID-19) in Italy. JAMA. 2020; 323(14): 1335. https://doi.org/10.1001/jama.2020.4344.
  • Onder G., Rezza G., Brusaferro S. Case-Fatality Rate and Characteristics of Patients Dying in Relation to COVID-19 in Italy. JAMA. 2020; 323(18): 1775-6. https://doi.org/10.1001/jama.2020.4683.
  • Remuzzi A., Remuzzi G. COVID-19 and Italy: what next? The Lancet. 2020; 395(10231): 1225-8. https://doi.org/10.1016/S0140-6736(20)30627-9.
  • Hollander J.E., Carr B.G. Virtually Perfect? Telemedicine for COVID-19. N Engl J Med. 2020; 382(18): 1679-81. https://doi.org/10.1056/NEJMp2003539.
  • Ueda M., Martins R., Hendrie P.C., McDonnell T., Crews J.R., Wong T.L., McCreery B., Jagels B., Crane A., Byrd D.R., Pergam S.A., Davidson N.E., Liu C., Stewart F.M. Managing Cancer Care During the COVID-19 Pandemic: Agility and Collaboration Toward a Common Goal. J Natl Compr Canc Netw. 2020; 20: 1-4. https://doi.org/10.6004/jnccn.2020.7560.
  • Extance A. COVID-19 and long term conditions: what if you have cancer, diabetes, or chronic kidney disease? BMJ. 2020; 368. https://doi.org/10.1136/bmj.m1174.
  • Deming W.E. Out of the crisis. 1986.
  • Liang W., Guan W., Chen R., Wang W., Li J., Xu K., Li C., Ai Q., Lu W., Liang H., Li S., He J. Cancer patients in SARS-CoV-2 infection: a nationwide analysis in China. Lancet Oncol. 2020; 21(3): 335-7. https://doi.org/10.1016/S1470-2045(20)30096-6.
  • Patel K., Choudhury A., Hoskin P., Varughese M., James N., Huddart R., Birtle A. Clinical Guidance for the Management of Patients with Urothelial Cancers During the COVID-19 Pandemic - Rapid Review. Clin Oncol (R Coll Radiol). 2020; 32(6): 347-53. https://doi.org/10.1016/j.clon.2020.04.005.
  • Biganzoli L., Cardoso F., Beishon M., Cameron D., Cataliotti L., Coles C.E., Delgado Bolton R.C., Trill M.D., Erdem S., Fjell M., Geiss R., Goossens M., Kuhl C., Marotti L., Naredi P., Oberst S., Palussière J., Ponti A., Rosselli Del Turco M., Rubio I.T., Sapino A., Senkus-Konefka E., Skelin M., Sousa B., Saarto T., Costa A., Poortmans P. The requirements of a specialist breast centre. Breast. 2020; 51: 65-84. https://doi.org/10.1016/j.breast.2020.02.003.
  • ASBrS ACR. ASBrS and ACR joint statement on breast screening exams during the COVID-19 pandemic. 2020.
  • ASCO. Care of individuals with cancer during COVID-19. 2020.
  • ASBrS. Recommendations for prioritization, treatment and triage of breast cancer patients during the COVID-19 pandemic: executive summary. 2020.
  • ECCO. Statement on COVID-19 from the European cancer organization’s board of directors. 2020.
  • ACS. COVID-19. Guidance for triage of non-emergent surgical procedures. 2020.
  • ACS. COVID-19. Recommendations for management of elective surgical procedures. 2020.
  • ASPS. Statement on breast reconstruction in the face of COVID-19 pandemic. 2020.
  • Coles C.E., Aristei C., Bliss J., Boersma L., Brunt A.M., Chatterjee S., Hanna G., Jagsi R., Kaidar Person O., Kirby A., Mjaaland I., Meattini I., Luis A.M., Marta G.N., Offersen B., Poortmans P., Rivera S. International Guidelines on Radiation Therapy for Breast Cancer During the COVID-19 Pandemic. Clin Oncol (R Coll Radiol). 2020 May; 32(5): 279-81. https://doi.org/10.1016/j.clon.2020.03.006.
  • van Maaren M.C., Bretveld R.W., Jobsen J.J., Veenstra R.K., Groothuis-Oudshoorn C.G., Struikmans H., Maduro J.H., Strobbe L.J., Poortmans P.M., Siesling S. The influence of timing of radiation therapy following breast-conserving surgery on 10-year disease-free survival. Br J Cancer. 2017; 117(2): 179-88. https://doi.org/10.1038/bjc.2017.159.
  • Haviland J.S., Owen J.R., Dewar J.A., Agrawal R.K., Barrett J., Barrett-Lee P.J., Dobbs H.J., Hopwood P., Lawton P.A., Magee B.J., Mills J., Simmons S., Sydenham M.A., Venables K., Bliss J.M., Yarnold J.R.; START Trialists’ Group. The UK Standardisation of Breast Radiotherapy (START) trials of radiotherapy hypofractionation for treatment of early breast cancer: 10-year follow-up results of two randomised controlled trials. Lancet Oncol. 2013; 14(11): 1086-94. https://doi.org/10.1016/S1470-2045(13)70386-3.
  • Whelan T.J., Pignol J.-P., Levine M.N., Julian J.A., MacKenzie R., Parpia S., Shelley W., Grimard L., Bowen J., Lukka H., Perera F., Fyles A., Schneider K., Gulavita S., Freeman C. Long-term results of hypofractionated radiation therapy for breast cancer. N Engl J Med. 2010; 362(6): 513-20. https://doi.org/10.1056/NEJMoa0906260.
  • Brunt A.M., Haviland J., Sydenham M., Algurafi H., Alhasso A., Bliss P., Bloomfield D., Emson M., Goodman A., Harnett A., Passant H., Tsang Y.M., Wheatley D., Bliss J., Yarnold J. FAST phase III RCT of radiotherapy hypofractionation for treatment of early breast cancer: 10-year results (CRUKE/04/015). Int J Radiat Oncol Biol Phys 2018; 102(5): 1603-4.
  • Brunt A.M., Wheatley D., Yarnold J., Somaiah N., Kelly S., Harnett A., Coles C., Goodman A., Bahl A., Churn M., Zotova R., Sydenham M., Griffin C.L., Morden J.P., Bliss J.M.; FAST-Forward Trial Management Group. Acute skin toxicity associated with a 1-week schedule of whole breast radiotherapy compared with a standard 3-week regimen delivered in the UK FAST-Forward Trial. Radiother Oncol. 2016; 120(1): 114-8. https://doi.org/10.1016/j.radonc.2016.02.027.
  • Leong N., Truong P.T., Tankel K., Kwan W., Weir L., Olivotto I.A. Hypofractionated Nodal Radiation Therapy for Breast Cancer Was Not Associated With Increased Patient-Reported Arm or Brachial Plexopathy Symptoms. Int J Radiat Oncol Biol Phys. 2017; 99(5): 1166-72. https://doi.org/10.1016/j.ijrobp.2017.07.043.
  • Brunt A. M., Haviland J., Sydenham M.A., Al-hasso A., Bloomfield D., Chan C., Churn M., Cleator S., Coles C., Emson M., Goodman A., Griffin C.L., Harnett A., Hopwood P., Kirby A.M., Kirwan C., Morris C., Sawyer E., Somaiah N., Syndikus I., Wilcox M., Zotova R., Wheatley D., Bliss J., Yarnold J. OC-0595: FAST-Forward phase 3 RCT of 1-week hypofractionated breast radiotherapy:3-year normal tissue effects. Radiother Oncol 2018; 127: 311-2.
  • Bartelink H., Maingon P., Poortmans P., Weltens C., Fourquet A., Jager J., Schinagl D., Oei B., Rodenhuis C., Horiot J.-C., Struikmans H., Van Limbergen E., Kirova Y., Elkhuizen P., Bongartz R., Miralbell R., Morgan D., Dubois J.-B., Remouchamps V., Mirimanoff R.-O., Collette S., Collette L; European Organisation for Research and Treatment of Cancer Radiation Oncology and Breast Cancer Groups. Whole-breast irradiation with or without a boost for patients treated with breast-conserving surgery for early breast cancer: 20-year follow-up of a randomised phase 3 trial. Lancet Oncol. 2015; 16(1): 47-56. https://doi.org/10.1016/S1470-2045(14)71156-8.
  • Coles C.E., Griffin C.L., Kirby A.M., Titley J., Agrawal R.K., Alhasso A., Bhattacharya I.S., Brunt A.M., Ciurlionis L., Chan C., Donovan E.M., Emson M.A., Harnett A.N., Haviland J.S., Hopwood P., Jefford M.L., Kaggwa R., Sawyer E.J., Syndikus I., Tsang Y.M., Wheatley D.A., Wilcox M., Yarnold J.R., Bliss J.M.; IMPORT Trialists. Partial-breast radiotherapy after breast conservation surgery for patients with early breast cancer (UK IMPORT LOW trial): 5-year results from a multicentre, randomised, controlled, phase 3, non-inferiority trial. Lancet. 2017; 390(10099): 1048-60. https://doi.org/10.1016/S0140-6736(17)31145-5.
  • Livi L., Meattini I., Marrazzo L., Simontacchi G., Pallotta S., Saieva C., Paiar F., Scotti V., De Luca Cardillo C., Bastiani P., Orzalesi L., Casella D., Sanchez L., Nori J., Fambrini M., Bianchi S. Accelerated partial breast irradiation using intensity-modulated radiotherapy versus whole breast irradiation: 5-year survival analysis of a phase 3 randomised controlled trial. Eur J Cancer. 2015; 51(4): 451-63. https://doi.org/10.1016/j.ejca.2014.12.013.
  • Veronesi U., Orecchia R., Maisonneuve P., Viale G., Rotmensz N., Sangalli C., Luini A., Veronesi P., Galimberti V., Zurrida S., Leonardi M.C., Lazzari R., Cattani F., Gentilini O., Intra M., Caldarella P., Ballardini B. Intraoperative radiotherapy versus external radiotherapy for early breast cancer (ELIOT): a randomised controlled equivalence trial. Lancet Oncol. 2013; 14(13): 1269-77. https://doi.org/10.1016/S1470-2045(13)70497-2.
  • Kunkler I.H., Williams L.J., Jack W.J., Cameron D.A., Dixon J.M.; PRIME II investigators. Breast-conserving surgery with or without irradiation in women aged 65 years or older with early breast cancer (PRIME II): a randomised controlled trial. Lancet Oncol. 2015; 16(3): 266-73. https://doi.org/10.1016/S1470-2045(14)71221-5.
  • Cardoso F., Kyriakides S., Ohno S., Penault-Llorca F., Poortmans P., Rubio I.T., Zackrisson S., Senkus E; ESMO Guidelines Committee. Early breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2019; 30(10): 1674. https://doi.org/10.1093/annonc/mdz189.
  • Earl H.M., Hiller L., Vallier A.L., Loi S., McAdam K., Hughes- Davies L., Harnett A.N., Ah-See M.L., Simcock R., Rea D., Raj S., Woodings P., Harries M., Howe D., Raynes K., Higgins H.B., Wilcox M., Plummer C., Mansi J., Gounaris I., Mahler-Araujo B., Provenzano E., Chhabra A., Abraham J.E., Caldas C., Hall P.S., McCabe C., Hulme C., Miles D., Wardley A.M., Cameron D.A., Dunn J.A.; PERSEPHONE Steering Committee and Trial Investigators. 6 versus 12 months of adjuvant trastuzumab for HER2-positive early breast cancer (PERSEPHONE): 4-year disease-free survival results of a randomised phase 3 non-inferiority trial. Lancet. 2019; 393(10191): 2599-2612. https://doi.org/10.1016/S0140-6736(19)30650-6.
  • Cardoso F., Senkus E., Costa A., Papadopoulos E., Aapro M., André F., Harbeck N., Aguilar Lopez B., Barrios C.H., Bergh J., Biganzoli L., Boers-Doets C.B., Cardoso M.J., Carey L.A., Cortés J., Curigliano G., Diéras V., El Saghir N.S., Eniu A., Fallowfield L., Francis P.A., Gelmon K., Johnston S.R.D., Kaufman B., Koppikar S., Krop I.E., Mayer M., Nakigudde G., Offersen B.V., Ohno S., Pagani O., Paluch-Shimon S., Penault-Llorca F., Prat A., Rugo H.S., Sledge G.W., Spence D., Thomssen C., Vorobiof D.A., Xu B., Norton L., Winer E.P. 4th ESO-ESMO International Consensus Guidelines for Advanced Breast Cancer (ABC 4). Ann Oncol. 2018; 29(8): 1634-57. https://doi.org/10.1093/annonc/mdy192.
  • D’Ippolito S., Shams M., Ambrosini E., Calì G., Pastorelli D. R1 - the effect of loneliness on cancer mortality. Ann Oncol. 2017; 28: 82-88. https://doi.org/10.1093/annonc/mdx434.
  • Hill E.M., Hamm A. Intolerance of uncertainty, social support, and loneliness in relation to anxiety and depressive symptoms among women diagnosed with ovarian cancer. Psychooncology. 2019; 28(3): 553-60. https://doi.org/10.1002/pon.4975.
  • Holt-Lunstad J., Smith T.B., Baker M., Harris T., Stephenson D. Loneliness and social isolation as risk factors for mortality: a meta-analytic review. Perspect Psychol Sci. 2015; 10(2): 227-37. https://doi.org/10.1177/1745691614568352.
  • Bortolato B., Hyphantis T.N., Valpione S., Perini G., Maes M., Morris G., Kubera M., Köhler C.A., Fernandes B.S., Stubbs B., Pavlidis N., Carvalho A.F. Depression in cancer: The many biobehavioral pathways driving tumor progression. Cancer Treat Rev. 2017; 52: 58-70. https://doi.org/10.1016/j.ctrv.2016.11.004.
  • Reis J.C., Antoni M.H., Travado L. Emotional distress, brain functioning, and biobehavioral processes in cancer patients: a neuroimaging review and future directions. CNS Spectr. 2020; 25(1): 79-100. https://doi.org/10.1017/S1092852918001621.
  • Annunziata M. A., Muzzatti B., Bidoli E., Flaiban C., Bomben F., Piccinin M., Gipponi K.M., Mariutti G., Busato S., Mella S. Hospital anxiety and depression Scale (HADS) accuracy in cancer patients. Suppor Care Cancer. 2019; 28: 3921-6. https://doi.org/10.1007/s00520-019-05244-8.
Еще
Статья научная
QR-код для установки приложения SciUp Наведите камеру и скачайте бесплатное приложение SciUp